Sep 15, 2023 · Response rates are variable and many treatments pose challenges for patient adherence. Therapies that are easy to administer, regulate underlying type 2 inflammation, and …

Learn more about DUPIXENT® (dupilumab), the first FDA-approved biologic to treat eosinophilic esophagitis (EoE) in adult and pediatric patients aged 1 year and older who weigh at least 33lb …

Feb 20, 2024 · The Consumer’s Guide to Biologics for Eosinophilic Esophagitis Learn everything you need to know about the first FDA-approved treatment for eosinophilic esophagitis.

Oct 9, 2025 · Does Dupixent Treat Eosinophilic Dermatitis (EOE)? Dupixent (dupilumab) is the first and only FDA-approved biologic treatment for eosinophilic esophagitis (EoE). It is indicated for adult and …

Jun 12, 2024 · Dupixent is an injectable biologic medicine. Here’s how it helps with eosinophilic esophagitis.

Dupixent is an FDA-approved biologic therapy that targets specific proteins involved in inflammation. By blocking these proteins, it reduces esophageal inflammation and alleviates symptoms of eosinophilic …

Jan 1, 2023 · Dupilumab is the first Food and Drug Administration–approved therapy for EoE. Other studies evaluating biologics that target eosinophils, key cytokines, and inflammatory pathways in …

Feb 25, 2023 · The recent approval of dupilumab for treatment of eosinophilic esophagitis (EOE), research into better biomarkers, and the anticipated availability of a metric to assess EOE severity all …

Dec 21, 2024 · Our findings suggest that the biologics currently being investigated are considered safe and effective treatments for EoE, while their efficiency varies. However, the discussion of biologics in …

Jun 12, 2023 · Dupilumab, a monoclonal antibody to IL-4 receptor alpha, is the first biologic treatment for EoE approved by the FDA. It is approved for EoE in children 1 year and older who weigh at least 15 …